Damian Inlall
Senior Associate Director, Medicine Capability Excellence Owner Boehringer Ingelheim
Damian Inlall, Senior Associate Director, Medicine Capability Excellence Owner at Boehringer Ingelheim Pharmaceuticals, leads U.S. Expanded Access strategy. He drove the cross-functional design of a local governance framework aligned to 21 CFR 312 Subpart I and supported the development and implementation of BOOST, the company’s first global, enterprise-level digital platform created to facilitate end-to-end management of Individual Patient Expanded Access requests. With 15+ years in clinical operations across health systems, biotech, and pharma, he brings site and sponsor perspectives to building compliant access programs.
Seminars
Tuesday 23rd March 2027
Workshop B – Building SOPs, Governance Structures & Internal Alignment for New Expanded Access Teams
11:00 am
- Defining ownership across Medical, Regulatory, Clinical Operations and Supply
- Determining which clinical trial processes should be adapted for EAPs
- Building governance structures and approval workflows
- Securing internal buy-in and managing cross-functional stakeholders
